Biocon Limited — Updates, 30-01-2025: Press Release

Biocon has reported consolidated revenue of Rs 3,856 Cr for the third quarter, reflecting a 7% increase year-on-year. Operating revenue also rose by 10%, hitting Rs 3,821 Cr. The EBITDA at Rs 787 Cr marks a 16% growth, while the net profit stood at Rs 25 Cr. The biosimilars segment was particularly strong, achieving Rs 2,289 Cr, up 14% year-on-year, and reflecting solid growth momentum.

Strategically, the company's recent advancements in regulatory approvals for key products like bUstekinumab will facilitate forthcoming launches and bolster growth prospects. Syngene's revenue also rebounded, with an 11% increase in operating revenue driven by improved performance across all divisions. The outlook remains positive, supported by ongoing initiatives and market expansion, particularly in the U.S. and Europe, where market shares for major products are increasing. Investors should watch for continued progress in product launches and market penetration as these developments may lead to further growth opportunities.